INmune Bio (INMB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
The meeting was called to order virtually to increase inclusivity and reach more stockholders.
The agenda and order of business were outlined, with business matters addressed first and Q&A scheduled for the end.
Board and executive committee updates
Nominees for board election included David Moss, Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen.
Shareholder proposals
Three proposals were presented: election of directors, ratification of the independent auditor, and approval of the amended 2021 Stock Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from INmune Bio
- CORDStrom and XPro1595 advance to pivotal stages, targeting systemic RDEB and Alzheimer's.INMB
Corporate presentation4 Jun 2026 - Net loss narrowed, cash reserves strong, but liquidity concerns persist amid regulatory progress.INMB
Q1 20267 May 2026 - Virtual meeting to elect directors, ratify auditor, and expand equity plan with evergreen provision.INMB
Proxy filing23 Apr 2026 - Late-stage clinical progress and regulatory filings drive 2026 outlook; cash runway through Q1 2027.INMB
Q4 202530 Mar 2026 - Late-stage therapies for RDEB and Alzheimer's advance toward 2026 filings, showing strong efficacy.INMB
Corporate presentation16 Mar 2026 - CORDStrom reduced itch and pain, improved healing, and showed strong safety in RDEB children.INMB
Study update26 Feb 2026 - Q2 net loss was $9.7M, $14.5M was raised, and $31.1M cash remains as clinical trials advance.INMB
Q2 20242 Feb 2026 - Alzheimer's and prostate cancer trials progress, net loss widens, key data expected in 2025.INMB
Q3 202417 Jan 2026 - Phase II Alzheimer's data and CORDStrom BLA filing set for 2025 amid robust R&D and financing.INMB
Q4 202425 Dec 2025